Navigation Links
Diagnoplex Closes CHF10 Million ($8.3 Million) Series A Financing
Date:12/10/2008

LAUSANNE, Switzerland, December 10 /PRNewswire/ -- Diagnoplex, a developer of molecular cancer diagnostics today announced the closing of a Series A financing raising CHF10 million ($8.3 million). The A-round was led by Novartis Venture Fund and NeoMed, with Initiative Capital Romandie acting as co-investor. The Novartis Venture Fund was also a seed investor in the company. BCCC Avocats acted as counsel to the investors and BMP Associés acted as counsel to the company.

In connection with the financing, Anja König, Ph.D., a Managing Director of Novartis Venture Fund, and Thomas Goebel, Ph.D., a Principal at NeoMed, will join Diagnoplex' board of directors, while Claude Suard, Partner at DEFI Gestion, will join the board as an observer.

Diagnoplex technology platform

Leveraging its unique and proprietary molecular platform capabilities, Diagnoplex develops blood-based cancer diagnostics. Diagnoplex' single-channel quantitative multiplex reverse transcriptase-polymerase chain reaction (scqmRT-PCR) yields the quantification of copy number obtained with real-time PCR, and allows quantifying up to 60 genes simultaneously. The scqmRT-PCR platform offers several important competitive advantages. It pairs the high accuracy and reliability of PCR with the possibility to read out multi-gene signatures of different cancers. As opposed to microarray platforms, it is easily scalable and can be run in most standard testing laboratories. Stavros Therianos, PhD, founder and chief executive officer of Diagnoplex, developed the platform during his tenure at Rochester University, NY.

Diagnoplex lead product - Colox

Diagnoplex will use the proceeds from the financing to support the further clinical development of its lead product Colox, a non-invasive test for the early detection of colon cancer, which will be made available as a ready-to-use clinical laboratory kit. Early result
'/>"/>

SOURCE Diagnoplex
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
2. Genmab Discloses Target and Development Plans for HuMax-Inflam
3. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
4. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
5. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
6. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
7. BioVex Closes Second Round of Series E Financing
8. Pharmaxis Closes Share Purchase Plan
9. The closest look ever at native human tissue
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2010)... PARK, Md. -- University of Maryland researchers have ... computational techniques to analyze patterns of improvised explosive ... locations and predict the locations of weapons caches ... attacks. , University of Maryland computer science Ph.D. ... Subrahmanian, together with University of Torino (Italy) computer ...
(Date:2/5/2010)... Cardiovascular Disease ,, COLLEGE PARK, Md. ... Life Inc. ( www.renovalife.com ), a company developing ... has joined the Maryland Technology Enterprise Institute (Mtech) ... today. ,, The privately funded company, founded in ... month. ,, "The most important factors [for joining ...
(Date:2/5/2010)... -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced ... Officer, will be presenting a corporate overview of the ... Conference. Transgenomic,s presentation will take place at 11:30 ... at The Waldorf- Astoria in New ... Inc. ,, Transgenomic, Inc. (OTC BB: ...
(Date:2/5/2010)... CRANBURY, N.J. , Feb. 5 ... its Board of Directors has elected John F. ... to his current role as Chief Executive Officer (CEO), ... Hayden, Jr. , who will become the Lead Independent ... elect Mr. Crowley as Chairman of the Board reflects ...
Breaking Biology Technology:'Fighting' IED attacks with SCARE technology 2'Fighting' IED attacks with SCARE technology 3Renova Life Inc. Joins Mtech Incubator 2Renova Life Inc. Joins Mtech Incubator 3Transgenomic Presents at 12th Annual BIO CEO & Investor Conference 2Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board 2
... Wauwatosa, Wis. - A Medical College of Wisconsin ... to study salt-sensitive high blood pressure. , ,The grant was ... to evaluate the impact that genes within specific regions ... kidney failure. According to the institute, high blood pressure, also ...
... Corp. , a $6 billion-a-year information technology product and services ... the stock of Madison-based Berbee Information Networks Corp. ... has been approved by the boards of both companies, is ... regulatory approvals and approval by Berbee shareholders. , ,Berbee, which ...
... knows the University of Wisconsin-Madison stimulates the ... new study has produced figures to back that assertion. ... University Research Park , located three miles west ... And the concentration of these innovative firms, according to ...
Other Biology Technology:Medical College receives $11 million grant to study high blood pressure 2Berbee believes acquisition by CDW will make it a national IT player 2Berbee believes acquisition by CDW will make it a national IT player 3Impact of research park firms pegged at $680M 2
(Date:2/9/2010)... have identified a gene they say is a strong ... other maladies associated with the natural flux in hormones ... in the Proceedings of the National Academy of ... showing that a common human variant of the gene ... estrogen on the brain, impairing memory. If applied in ...
(Date:2/9/2010)... Calif. -- OlFactor Laboratories, Inc., a majority owned ... to patented technology from UC Riverside. , ... understanding of how two-winged blood-feeding insects, e.g. mosquitos ... detect carbon dioxide (CO2) emissions from animals and ... human and animal breath, attracts the insect to ...
(Date:2/8/2010)... and summers has been accelerating, according to a ... scientific journal Global Change Biology . ... UK research institutions, universities and conservation organisations, is ... of long-term changes in the seasonal timing (phenology) ... environments in the UK. , Led by ...
Breaking Biology News(10 mins):Research identifies gene with likely role in premenstrual disorder 2Research identifies gene with likely role in premenstrual disorder 3Will earlier springs throw nature out of step? 2Child Neurology Foundation Announces 2430 000 Grant for Research Into Cause and Treatment of Infantile Spasms 60236 1Child Neurology Foundation Announces 2430 000 Grant for Research Into Cause and Treatment of Infantile Spasms 60236 2Child Neurology Foundation Announces 2430 000 Grant for Research Into Cause and Treatment of Infantile Spasms 60236 3Elekta Demonstrates Continued Leadership in Image Guidance at 2009 ASTRO Annual Meeting 5785 1Elekta Demonstrates Continued Leadership in Image Guidance at 2009 ASTRO Annual Meeting 5785 2Elekta Demonstrates Continued Leadership in Image Guidance at 2009 ASTRO Annual Meeting 5785 3Elekta Demonstrates Continued Leadership in Image Guidance at 2009 ASTRO Annual Meeting 5785 4SMU geothermal conference 10556 1SMU geothermal conference 10556 2
... Mayo Clinic researchers report that the expression of two novel ... cancer may allow identification of women who are and are ... Results of the study are published in the April 1 ... gene profile was previously discovered as a potential marker of ...
... new method of delivering chemotherapy to cancer patients without incurring ... developed. , The method, produced at the University of ... the chemotherapy drug which are then implanted into the cancerous ... and compatible with body tissue, which means they would not ...
... A potentially ground-breaking treatment for nerve damage caused by ... patient trials. , The University of Manchester team has ... by stimulating a person's genes may prevent nerve damage ... disease. , The positive preclinical results ?reported in the ...
Other Biology News:Mayo Clinic study finds two genes predict outcome for breast cancer patients 2New device could cut chemotherapy deaths 2Trial success for diabetic nerve therapy 2
11-keto Testosterone EIA Antiserum hormones steroids antisera antiserum eias enzyme immunoassays reagents 11-keto-testosterone...
Goat polyclonal to CHMP5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-NKDGVLVDEFGLPQ, corresponding to C terminal amino acids 202-215 of Human CHMP5 Entrez GeneID: ...
Yields DNA greater than 50 kb in length from yeast, fungi, Gram neg. and Gram pos. bacteria...
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
Biology Products: